These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 29792708)

  • 1. Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
    Jamwal R; de la Monte SM; Ogasawara K; Adusumalli S; Barlock BB; Akhlaghi F
    Mol Pharm; 2018 Jul; 15(7):2621-2632. PubMed ID: 29792708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease.
    Woolsey SJ; Mansell SE; Kim RB; Tirona RG; Beaton MD
    Drug Metab Dispos; 2015 Oct; 43(10):1484-90. PubMed ID: 26231377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro to In Vivo Scalars for Drug Clearance in Nonalcoholic Fatty Liver and Steatohepatitis.
    Sierra T; Achour B
    Drug Metab Dispos; 2024 Apr; 52(5):390-398. PubMed ID: 38423789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver.
    Rau M; Schilling AK; Meertens J; Hering I; Weiss J; Jurowich C; Kudlich T; Hermanns HM; Bantel H; Beyersdorf N; Geier A
    J Immunol; 2016 Jan; 196(1):97-105. PubMed ID: 26621860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New aspects of nonalcoholic steatohepatitis].
    Stefan N
    Internist (Berl); 2019 Feb; 60(2):128-132. PubMed ID: 30645665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.
    Boutari C; Lefkos P; Athyros VG; Karagiannis A; Tziomalos K
    Curr Vasc Pharmacol; 2018; 16(3):214-218. PubMed ID: 28676025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
    Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
    J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
    Polasek TM; Miners JO
    Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
    Guo J; Zhou D; Li Y; Khanh BH
    Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic (PBPK) Model Predictions of Disease Mediated Changes in Drug Disposition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD).
    Adiwidjaja J; Spires J; Brouwer KLR
    Pharm Res; 2024 Mar; 41(3):441-462. PubMed ID: 38351228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of two-photon fluorescent probes for carboxylesterase and ONOO
    Jiao X; Wang Y; Zhang J; Wang X
    Talanta; 2024 Apr; 270():125521. PubMed ID: 38091750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.
    Hamaoka N; Oda Y; Hase I; Mizutani K; Nakamoto T; Ishizaki T; Asada A
    Clin Pharmacol Ther; 1999 Aug; 66(2):110-7. PubMed ID: 10460064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A useful model capable of predicting the clearance of cytochrome 3A4 (CYP3A4) substrates in humans: validity of CYP3A4 transgenic mice lacking their own Cyp3a enzymes.
    Mitsui T; Nemoto T; Miyake T; Nagao S; Ogawa K; Kato M; Ishigai M; Yamada H
    Drug Metab Dispos; 2014 Sep; 42(9):1540-7. PubMed ID: 25005602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus.
    Jung Y; Koo BK; Jang SY; Kim D; Lee H; Lee DH; Joo SK; Jung YJ; Park JH; Yoo T; Choi M; Lee MK; Kang SW; Chang MS; Kim W; Hwang GS;
    Liver Int; 2021 Dec; 41(12):2892-2902. PubMed ID: 34358397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
    Mao J; Johnson TR; Shen Z; Yamazaki S
    Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH).
    Murphy WA; Adiwidjaja J; Sjöstedt N; Yang K; Beaudoin JJ; Spires J; Siler SQ; Neuhoff S; Brouwer KLR
    Clin Pharmacol Ther; 2023 Feb; 113(2):275-297. PubMed ID: 35429164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
    Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
    Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100A9: A Potential Biomarker for the Progression of Non-Alcoholic Fatty Liver Disease and the Diagnosis of Non-Alcoholic Steatohepatitis.
    Liu X; Wang Y; Ming Y; Song Y; Zhang J; Chen X; Zeng M; Mao Y
    PLoS One; 2015; 10(5):e0127352. PubMed ID: 25993652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.